PMC:7408073 / 99245-99577 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T514","span":{"begin":285,"end":292},"obj":"Body_part"}],"attributes":[{"id":"A514","pred":"fma_id","subj":"T514","obj":"http://purl.org/sig/ont/fma/fma83365"}],"text":"Chronic administration (about 4 weeks) of C-16/DLM-4760 in combination with ACE2 activating treatments was performed by daily intraperitoneal injection at a dose of 25mg/kg in distilled water (as a solution of 42 mg/mL) or 0.9% sterile saline (as a solution of 84 mg/mL using a 0.5-mL insulin syringe) freshly prepared [52,183,184]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3457","span":{"begin":76,"end":80},"obj":"Gene"},{"id":"3458","span":{"begin":285,"end":292},"obj":"Gene"},{"id":"3459","span":{"begin":186,"end":191},"obj":"Chemical"}],"attributes":[{"id":"A3457","pred":"tao:has_database_id","subj":"3457","obj":"Gene:59272"},{"id":"A3458","pred":"tao:has_database_id","subj":"3458","obj":"Gene:3630"},{"id":"A3459","pred":"tao:has_database_id","subj":"3459","obj":"MESH:D014867"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Chronic administration (about 4 weeks) of C-16/DLM-4760 in combination with ACE2 activating treatments was performed by daily intraperitoneal injection at a dose of 25mg/kg in distilled water (as a solution of 42 mg/mL) or 0.9% sterile saline (as a solution of 84 mg/mL using a 0.5-mL insulin syringe) freshly prepared [52,183,184]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T552","span":{"begin":47,"end":50},"obj":"Disease"},{"id":"T553","span":{"begin":228,"end":235},"obj":"Disease"}],"attributes":[{"id":"A552","pred":"mondo_id","subj":"T552","obj":"http://purl.obolibrary.org/obo/MONDO_0016745"},{"id":"A553","pred":"mondo_id","subj":"T553","obj":"http://purl.obolibrary.org/obo/MONDO_0005047"}],"text":"Chronic administration (about 4 weeks) of C-16/DLM-4760 in combination with ACE2 activating treatments was performed by daily intraperitoneal injection at a dose of 25mg/kg in distilled water (as a solution of 42 mg/mL) or 0.9% sterile saline (as a solution of 84 mg/mL using a 0.5-mL insulin syringe) freshly prepared [52,183,184]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1214","span":{"begin":42,"end":46},"obj":"http://purl.obolibrary.org/obo/CLO_0002096"},{"id":"T1215","span":{"begin":81,"end":91},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1216","span":{"begin":155,"end":156},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1217","span":{"begin":196,"end":197},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1218","span":{"begin":247,"end":248},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1219","span":{"begin":276,"end":277},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1220","span":{"begin":285,"end":292},"obj":"http://purl.obolibrary.org/obo/PR_000009054"}],"text":"Chronic administration (about 4 weeks) of C-16/DLM-4760 in combination with ACE2 activating treatments was performed by daily intraperitoneal injection at a dose of 25mg/kg in distilled water (as a solution of 42 mg/mL) or 0.9% sterile saline (as a solution of 84 mg/mL using a 0.5-mL insulin syringe) freshly prepared [52,183,184]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T63759","span":{"begin":186,"end":191},"obj":"Chemical"},{"id":"T53319","span":{"begin":198,"end":206},"obj":"Chemical"},{"id":"T52282","span":{"begin":249,"end":257},"obj":"Chemical"},{"id":"T57829","span":{"begin":285,"end":292},"obj":"Chemical"}],"attributes":[{"id":"A80010","pred":"chebi_id","subj":"T63759","obj":"http://purl.obolibrary.org/obo/CHEBI_15377"},{"id":"A64519","pred":"chebi_id","subj":"T53319","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A47465","pred":"chebi_id","subj":"T52282","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A40789","pred":"chebi_id","subj":"T57829","obj":"http://purl.obolibrary.org/obo/CHEBI_145810"}],"text":"Chronic administration (about 4 weeks) of C-16/DLM-4760 in combination with ACE2 activating treatments was performed by daily intraperitoneal injection at a dose of 25mg/kg in distilled water (as a solution of 42 mg/mL) or 0.9% sterile saline (as a solution of 84 mg/mL using a 0.5-mL insulin syringe) freshly prepared [52,183,184]."}

{"project":"2_test","denotations":[{"id":"32708755-20797602-20679030","span":{"begin":320,"end":322},"obj":"20797602"},{"id":"32708755-23370913-20679031","span":{"begin":323,"end":326},"obj":"23370913"},{"id":"32708755-31982938-20679032","span":{"begin":327,"end":330},"obj":"31982938"}],"text":"Chronic administration (about 4 weeks) of C-16/DLM-4760 in combination with ACE2 activating treatments was performed by daily intraperitoneal injection at a dose of 25mg/kg in distilled water (as a solution of 42 mg/mL) or 0.9% sterile saline (as a solution of 84 mg/mL using a 0.5-mL insulin syringe) freshly prepared [52,183,184]."}